Skip to main content
Premium Trial:

Request an Annual Quote

OpGen to Distribute Menarini Silicon Cellsearch Platform in North America for COVID-19 Applications

NEW YORK – OpGen announced Monday it has inked a partnership with Menarini Silicon Biosystems to distribute and promote Menarini Silicon's Cellsearch Circulating Endothelial Cell (CEC) Kit in North America.

Financial and other terms of the deal were not disclosed.

Under the agreement, OpGen will market and sell Menarini Silicon's Cellsearch platform, CEC kit, and other COVID-19 related products in North America. The platform is for research use only, and is intended to enrich and enumerate CECs from whole blood, which is useful in studying the progression of COVID-19 and could help identify patients at risk of severe complications, OpGen said in a statement.

Both OpGen and Menarini Silicon said they intend to expand their portfolios of COVID-19 products and platforms, which OpGen will distribute commercially to infectious disease hospitals, labs, research centers, and other COVID-19 testing facilities. Bologna, Italy-based Menarini Silicon is a subsidiary of the multinational Menarini Group.

A. Menarini Diagnostics, the European diagnostics division of the Menarini Group, also has a strategic distribution partnership with OpGen subsidiary Curetis for products including its Unyvero platform in Europe, which has been in place since 2019.

Last month, Menarini Silicon said it will sell Healgen Scientific's rapid antibody detection kit for SARS-CoV-2 IgG and IgM antibodies in the US.